Arbutus Biopharma (ABUS) Is a Company that Wedbush Seems to Dislike as Downgrade in Given

March 19, 2018 - By Maria Brooks

 Arbutus Biopharma (ABUS) Is a Company that Wedbush Seems to Dislike as Downgrade in Given

Arbutus Biopharma (ABUS) Receives a Downgrade

Arbutus Biopharma (ABUS) was lowered by equity analysts at Wedbush from their past “Outperform” rating to a “Neutral” rating in a research report sent to investors on 19 March.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Coverage

Among 3 analysts covering Arbutus Biopharma Corporation (ABUS), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Arbutus Biopharma Corporation has $10.0 highest and $10 lowest target. $10’s average target is 94.17% above currents $5.15 stock price. Arbutus Biopharma Corporation had 4 analyst reports since January 4, 2018 according to SRatingsIntel. The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) earned “Neutral” rating by Wedbush on Monday, March 19. The company was maintained on Thursday, March 15 by FBR Capital.

The stock decreased 1.90% or $0.1 during the last trading session, reaching $5.15. About 69,892 shares traded. Arbutus Biopharma Corporation (ABUS) has declined 2.31% since March 19, 2017 and is downtrending. It has underperformed by 19.01% the S&P500.

Analysts await Arbutus Biopharma Corporation (NASDAQ:ABUS) to report earnings on March, 20. They expect $-0.39 EPS, down 2.63 % or $0.01 from last year’s $-0.38 per share. After $-0.17 actual EPS reported by Arbutus Biopharma Corporation for the previous quarter, Wall Street now forecasts 129.41 % negative EPS growth.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $283.61 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The company??s lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: